| Inbound Relationships |
Type |
Active |
Source |
Characteristic |
Refinability |
Group |
| Product containing precisely paracetamol 80 milligram/1 each conventional release oral capsule (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Product containing precisely paracetamol 160 milligram/1 each conventional release oral capsule (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| paracetamol dråber 80 mg/0,8 ml |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| paracetamol eliksir 80 mg/2,5 ml |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| paracetamol eliksir 80 mg/5 ml |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| paracetamol eliksir 160 mg/5 ml |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| paracetamol 500 mg/15 ml oral væske |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Product containing precisely paracetamol 48.2 milligram/1 milliliter conventional release oral solution (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Acetaminophen + chloralantipyrine + isometheptene mucate (1:1) 325mg/100mg/65mg capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| paracetamol 500 mg + chlorpheniraminmaleat 8 mg + phenylephrinhydrochlorid 40 mg kapselformet tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| paracetamol 120 mg + alkohol 7%v v + codeinphosphat 12 mg eliksir |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| paracetamol 120 mg + codeinphosphat 12 mg suspension |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Product containing precisely codeine phosphate 15 milligram and paracetamol 300 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Codeine phosphate 30 mg and paracetamol 300 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Product containing precisely codeine phosphate 60 milligram and paracetamol 300 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Acetaminophen + dichloralantipyrine + isometheptene mucate (1:1) 325mg/100mg/65mg capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Product containing precisely hydrocodone bitartrate 10 milligram and paracetamol 325 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Hydrocodone bitartrate 5 mg and paracetamol 325 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Hydrocodone bitartrate 10 mg and paracetamol 500 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Hydrocodone bitartrate 5 mg and paracetamol 500 mg oral capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Product containing precisely hydrocodone bitartrate 5 milligram and paracetamol 500 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Acetaminophen + hydrocodone bitartrate 500mg/7.5mg elixir |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Hydrocodone bitartrate 7.5 mg and paracetamol 500 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Hydrocodone bitartrate 5 mg and paracetamol 556 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Product containing precisely hydrocodone bitartrate 10 milligram and paracetamol 650 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Product containing precisely hydrocodone bitartrate 7.5 milligram and paracetamol 650 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Hydrocodone bitartrate 10 mg and paracetamol 660 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Product containing precisely hydrocodone bitartrate 7.5 milligram and paracetamol 750 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| paracetamol 500 mg + orphenadrincitrat 50 mg kapselformede tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| paracetamol 325 mg + oxycodonhydrochlorid 5 mg opløsning |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Product containing precisely oxycodone hydrochloride 5 milligram and paracetamol 325 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| paracetamol 500 mg + oxycodonhydrochlorid 5 mg kapselformet tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Product containing precisely oxycodone hydrochloride 5 milligram and paracetamol 500 milligram/1 each conventional release oral capsule (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| paracetamol + pentazocinhydrochlorid kapselformet 650 mg tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Product containing precisely paracetamol 300 milligram and phenyltoloxamine citrate 20 milligram and salicylamide 200 milligram/1 each conventional release oral capsule (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Paracetamol 300 mg and phenyltoloxamine citrate 20 mg and salicylamide 200 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Dextropropoxyphene napsylate 50 mg and paracetamol 325 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Dextropropoxyphene napsylate 100 mg and paracetamol 650 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Paracetamol 250 mg and salicylamide 600 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Acetaminophen 125mg suppository |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| paracetamol + hydrocodonbitartrat |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Tramadol (substance) |
Is a |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Dihydroergotamine (substance) |
Is a |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Acetaminophen 120mg suppository |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| paracetamol væske 160 mg/5 ml |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Acetaminophen 500mg tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Product containing precisely hydrocodone bitartrate 10 milligram and paracetamol 400 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Acetaminophen 250mg oro-dispersible tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Paracetamol 1g/sachet powder |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Poisoning caused by paracetamol |
Causative agent |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Product containing levomepromazine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Product containing paracetamol (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Product containing precisely butalbital 50 milligram and paracetamol 325 milligram/1 each conventional release oral capsule (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Butalbital 50 mg and caffeine 40 mg and codeine phosphate 30 mg and paracetamol 325 mg oral capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Product containing precisely butalbital 50 milligram and caffeine 40 milligram and paracetamol 325 milligram/1 each conventional release oral capsule (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Product containing precisely butalbital 50 milligram and caffeine 40 milligram and paracetamol 325 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Product containing precisely butalbital 50 milligram and caffeine 40 milligram and paracetamol 500 milligram/1 each conventional release oral capsule (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Product containing precisely butalbital 50 milligram and caffeine 40 milligram and paracetamol 500 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Butalbital 50 mg and paracetamol 325 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Product containing precisely butalbital 50 milligram and paracetamol 650 milligram/1 each conventional release oral capsule (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Butalbital 50 mg and paracetamol 650 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Caffeine 30 mg and dihydrocodeine tartrate 16 mg and paracetamol 356.4 mg oral capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Product containing precisely caffeine 100 milligram and isometheptene mucate 65 milligram and paracetamol 325 milligram/1 each conventional release oral capsule (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Product containing precisely dichloralphenazone 100 milligram and isometheptene 65 milligram and paracetamol 325 milligram/1 each conventional release oral capsule (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| paracetamol 500 mg + phenyltoloxamincitrat 30 mg kapselformede tabletter |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Paracetamol 500 mg and phenyltoloxamine citrate 50 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Paracetamol 500 mg and phenyltoloxamine citrate 60 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Paracetamol 650 mg and phenyltoloxamine citrate 50 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| paracetamol væske 650 mg/25 ml |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| paracetamol + pentazocinhydrochlorid |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Product containing dichloralphenazone and isometheptene and paracetamol (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Product containing precisely hydrocodone bitartrate 2.5 milligram and paracetamol 500 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| paracetamol + caffein + isometheptenmucat |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| paracetamol + phenyltoloxamincitrat |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| paracetamol + alkohol + codeinphosphat |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| paracetamol + orphenadrincitrat |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Product containing chlormezanone and paracetamol (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Acetaminophen+diphenhydramine hydrochloride |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Product containing butalbital and caffeine and paracetamol (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| paracetamol + oxycodonhydrochlorid |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Product containing butalbital and paracetamol (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Isometheptene mucate+acetaminophen |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| paracetamol + butalbital + caffein + codeinphosphat |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Product containing methionine and paracetamol (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Acetaminophen + dichloralantipyrine + isometheptene mucate |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Acetaminophen + chloralantipyrine + isometheptene mucate |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| paracetamol + propoxyphennapsylat |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Paracetamol 160 mg chewable tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| paracetamol + promethazinhydrochlorid |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| acetaminophen+ chlorpheniraminmaleat + phenylephrinhydrochlorid |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Product containing metoclopramide and paracetamol (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| paracetamol + domperidon |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| paracetamol + caffein + dihydrocodeinbitartrat |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Acetaminophen + codeine phosphate |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Codeine phosphate 15 mg and paracetamol 500 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Product containing precisely paracetamol 500 milligram/1 each conventional release effervescent oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Product containing precisely paracetamol 500 milligram and pseudoephedrine hydrochloride 30 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| paracetamol + pseudoephedrinhydrochlorid |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| paracetamol pulver 1 g/brev |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Paracetamol 250 mg orodispersible tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Product containing precisely caffeine 60 milligram and dihydrocodeine tartrate 32 milligram and paracetamol 712.8 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
FHIR